Despite missing the mark on progression-free survival, the trial remains active. The independent data monitoring committee advised the company to continue the study to assess the second primary endpoint: overall survival. BioNTech emphasized that achieving statistical significance in this remaining category would still constitute a successful trial outcome under the current design.
In section Market Quotes
BioNTech Cancer Immunotherapy Misses Key Progression Goal
A mid-to-late stage clinical trial for BioNTech’s BNT113 immunotherapy failed to hit its first dual primary endpoint, as the drug showed no statistically significant improvement in progression-free survival compared to standard pembrolizumab treatment in patients suffering from specific HPV-driven head and neck cancers.
The study evaluates BNT113 alongside pembrolizumab, targeting aggressive head and neck malignancies linked to the human papillomavirus. This setback highlights the volatility inherent in immunotherapy development, where dual-endpoint success is often required to establish clear clinical superiority over existing treatment protocols.
Comments (0)
No comments yet. Be the first!